iGRO™ assesses the innate capacity of a patient to grow in response to growth hormone (GH) treatment by calculating the index of responsiveness (IoR) at the end of the first year of treatment. 1
Growth responsiveness in the first year of GH treatment in terms of the IoR is a valuable parameter that determines long-term outcomes in response to GH. Growth responsiveness in the first year of GH treatment is an important predictor of both adult height and total gain in height in individuals with one of several growth disorders.
iGRO™ index of responsiveness chart.
iGRO™ plots the child’s IoR alongside those of children in the selected reference population.
On-going, interactive observation and analysis of growth responses using the iGRO™ growth chart during GH treatment make it possible to tailor therapy to meet the needs of the child and optimise the outcomes of treatment.
For example, a response smaller than predicted indicates that a patient is less responsive to GH than other children of the same age and with the same biological characteristics.
If both response and responsiveness are reduced, lack of adherence and unknown causes of growth impairment should be investigated.
1 - Loftus J, Lindberg A, Aydin F, et al. Journal of Pediatric Endocrinology and Metabolism (2017);30:1019–1026.